Is CYP1A2 useful for Darmgesundheit?

CYP1A2 is a phase I liver enzyme primarily involved in metabolizing caffeine, estrogens, and certain drugs. There is no direct scientific evidence supporting its usefulness for assessing or improving gut health (microbiome composition, intestinal barrier, or inflammation). Mechanistic hypotheses suggest that CYP1A2 activity might indirectly influence the gut microbiota via bile acid metabolism or xenobiotic clearance, but no clinical studies or reproducible associations exist. In nutrigenetics, CYP1A2 genotyping (e.g., rs762551) is mainly used to estimate caffeine sensitivity, not gut health. Therefore, a DNA test for CYP1A2 variants does not provide actionable information about the state of the gut. For those interested in gut health, validated approaches such as stool analysis (microbiome sequencing, calprotectin) and dietary interventions (fiber, probiotics) are more appropriate. The evidence for CYP1A2 in this context is mechanistic at best and insufficient for any recommendation.